Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
about
Oxidative stress, a trigger of hepatitis C and B virus-induced liver carcinogenesisHepatitis C-related hepatocellular carcinoma in the era of new generation antivirals.Real world efficacy and safety of ombitasvir, Paritaprevir/r+Dasabuvir+Ribavirin IN genotype 1B patients with HCV liver cirrhosis.Reciprocal antagonism between the netrin-1 receptor uncoordinated-phenotype-5A (UNC5A) and the hepatitis C virus.CXCL9-11 polymorphisms are associated with liver fibrosis in patients with chronic hepatitis C: a cross-sectional study.Increased incidence of liver cancer after successful DAA treatment of chronic hepatitis C: Fact or fiction?Long-term outcome of chronic hepatitis C virus infection in a real-world setting: The German LOTOS study.Are non-invasive fibrosis markers for chronic hepatitis B reliable in sub-Saharan Africa?Potential ultrastructure predicting factors for hepatocellular carcinoma in HCV infected patients.Management of Cirrhotic Patients After Successful HCV Eradication.Viral hepatitis and liver cancer.Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: A retrospective study.NS5ATP13 Promotes Liver Fibrogenesis Via Activation of Hepatic Stellate Cells.Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network.SIGNIFICANT IMPROVEMENT OF GLYCAEMIC CONTROL IN DIABETIC PATIENTS WITH HCV INFECTION RESPONDING TO DIRECT-ACTING ANTIVIRAL AGENTS.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.Hepatitis C Virus Clearance in Older Adults.Liver-related morbidity and mortality in patients with chronic hepatitis C and cirrhosis with and without sustained virologic response.Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant.Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment.Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis.Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease.Capacity of non-invasive hepatic fibrosis algorithms to replace transient elastography to exclude cirrhosis in people with hepatitis C virus infection: A multi-centre observational study.Leberkrebs: HCV wirkt nach.What do clinicians need to watch for with direct-acting antiviral therapy?The IL7RA rs6897932 polymorphism is associated with progression of liver fibrosis in patients with chronic hepatitis C: Repeated measurements design.Regulation of the Interferon Response by lncRNAs in HCV Infection.Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.Oncogenic Signaling Induced by HCV InfectionMolecular Mechanisms of Hepatocarcinogenesis Following Sustained Virological Response in Patients with Chronic Hepatitis C Virus InfectionLiver Disease Monitoring Practices After Hepatitis C Cure in the Underserved PopulationThe impact of antiviral therapy on hepatocellular carcinoma epidemiology
P2860
Q28075646-174C2033-CBDB-4A0D-BAE6-C509FAC487FDQ36306768-CECD10D4-9D3A-45E7-80A7-9D5117E06267Q38620762-02E78904-607C-4B90-866B-EA91F4F0528EQ38637134-4A7B9F33-2590-4475-AD54-5E2045D239E6Q38654167-C0F17ADE-1ED8-485E-9411-C2349C88EC85Q38763705-A83D2096-138A-4329-8388-6537A96E3681Q38936212-36C84BE8-7C66-483F-B58B-31113AC506E3Q38970883-631DC1BD-4B23-4A77-BAEA-7663ADA7C4ADQ39212821-8037CCE6-23AB-43D1-96C5-C522EB255C7EQ39260393-226DD47D-04A5-4653-8AAA-082D278D4F26Q40046596-3AE6BF28-62BD-45CB-966A-A7C69BC68A1DQ40053800-615192AF-8FBC-48BE-A925-5CA7E6D3A999Q40354039-ECB37446-197B-4A75-B7EB-D5CA879C0DA5Q41924669-907D6FA1-2DA6-49C8-A36A-615EFCFB6615Q41928201-08DADFA6-261F-4001-9586-4AB9AA864E3EQ41962614-49F632E7-1133-4771-9171-F2AA0B0407C7Q45324869-D9A811E2-9672-4280-BE8B-32D02759A069Q47123638-C6CD6904-2515-49F7-B4C1-B1B77EF64AA3Q47550704-C416CFBA-1B52-44C8-92AE-C916308551CBQ47569554-17E2E990-4725-449D-B1ED-90272F6A7E68Q47580656-8FDF0EB0-BDFD-44EB-B8D3-0063DA31AA63Q48089398-741D60C6-7A68-46D3-8C11-5396A43CC216Q49719507-E083DDD0-0BDB-46B3-A0F3-37DEA394875AQ50041788-798DE1C3-ADA6-4FAF-ACC3-0295DC8BB31AQ50086356-7E3D2E69-7DD4-48C5-9D22-29B257B14BB3Q52327014-BE96260B-6933-4103-9646-A16616841223Q54217219-A2DBF650-F00A-4464-8C6C-0DE716DC699DQ55122208-ECEE27A4-BCFA-4C06-ACF1-B978A5B2A088Q55348708-18B2E019-FEC6-452A-9850-4E5ECE9E1647Q57050806-1BEFADDD-1F50-4CD0-B02F-75DA3B26DFE9Q57067833-8DA3E376-5F72-4A88-9144-BED898368CAFQ57070319-41F02591-DA80-4383-A6EA-BB3307FE4349Q57301376-E6AF58D1-498C-42D5-B7C1-171D0B78F13E
P2860
Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Risk of cirrhosis-related comp ...... hepatitis C virus eradication.
@en
Risk of cirrhosis-related comp ...... hepatitis C virus eradication.
@nl
type
label
Risk of cirrhosis-related comp ...... hepatitis C virus eradication.
@en
Risk of cirrhosis-related comp ...... hepatitis C virus eradication.
@nl
prefLabel
Risk of cirrhosis-related comp ...... hepatitis C virus eradication.
@en
Risk of cirrhosis-related comp ...... hepatitis C virus eradication.
@nl
P2093
P50
P1476
Risk of cirrhosis-related comp ...... hepatitis C virus eradication
@en
P2093
Adriaan J van der Meer
Bart J Veldt
Bettina E Hansen
Conrado M Fernández-Rodríguez
Harald Hofer
Harry L A Janssen
Jordan J Feld
Karoline Rutter
Maria Trapero-Marugan
Massimo Colombo
P304
P356
10.1016/J.JHEP.2016.10.017
P577
2016-10-22T00:00:00Z